MULTIPLE MYELOMA

Paula Rodriguez Otero, MD, PhD, discusses promising results of linvoseltamab in high-risk smoldering multiple myeloma, highlighting its potential to prevent disease progression.

Paula Rodriguez Otero, MD, PhD, discusses linvoseltamab's manageable safety profile in high-risk smoldering multiple myeloma, highlighting promising study results.

A phase 2 study evaluates linvoseltamab's safety and efficacy in high-risk smoldering myeloma, focusing on response rates and MRD negativity.

During a live event, Adriana Rossi, MD, discussed easing CAR T-cell therapy access and highlighted cilta-cel's efficacy in earlier-line myeloma.

Experts explore the evolving treatment strategies for high-risk smoldering multiple myeloma, highlighting studies that show early intervention can improve patient outcomes.

Research explores innovative treatments for high-risk smoldering multiple myeloma, highlighting promising results from the bispecific antibody linvoseltamab.

The FDA approved Bosaya and Aukelso biosimilars, enhancing options for cancer-related bone loss, including in patients with multiple myeloma.

Binod Dhakal, MD, discusses the BOSTON trial of selinexor combination therapy in patients with relapsed/refractory multiple myeloma.

Recent advancements in multiple myeloma treatment highlight the promise of trispecific antibodies like JNJ-5322, potentially enhancing patient outcomes significantly.

A novel trispecific antibody, JNJ-5322, shows remarkable efficacy in treating multiple myeloma, achieving a 100% response rate in trials.

During a live event, Christopher J. Ferreri, MD, discussed findings on dose and schedule modifications of talquetamab in relapsed/refractory multiple myeloma.

Myeloma research faces funding uncertainties, yet collaboration and innovation drive optimism for breakthroughs in treatment and patient care.

During a live event, Christopher J. Ferreri, MD, discussed early- and late-presenting adverse events associated with talquetamab in relapsed/refractory multiple myeloma

The FDA approves Bildyos and Bilprevda, expanding treatment options for osteoporosis and cancer-related bone loss, enhancing patient access and affordability.

Jered Haddad transforms his cancer journey into a mission, cycling in Iceland to raise awareness and funds for multiple myeloma research.

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting in multiple myeloma.

FCARH143, a CAR T-cell therapy, delivered a 100% objective response rate in a phase 1 trial in patients with relapsed/refractory multiple myeloma.

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma therapy.

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted monoclonal antibody approach.

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with promising efficacy and safety profiles.

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing optimization.

Teclistamab shows promise for relapsed/refractory multiple myeloma patients with prior BCMA therapy, despite trends of reduced survival and response rates.

Shahzad Raza, MD, discusses the phase 2 RedirecTT-1 study which investigated the combination of talquetamab and teclistamab for treating patients with relapsed/refractory multiple myeloma complicated by extramedullary disease.

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in multiple myeloma.